Research programme: angiogenesis inhibitors - Targepeutics
Alternative Names: Angiogenesis inhibitors research programme - Targepeutics; TARG AA-201; TARG AA-202Latest Information Update: 16 Jul 2016
At a glance
- Originator Targepeutics
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 06 Sep 2005 Preclinical trials in Solid tumours in USA (unspecified route)